Center for Global Health R&D Policy Assessment

In thinking about neglected disease technologies, we often overlook the specialized needs of pediatric patients. Advocacy groups have done an excellent job in illuminating the gaps in appropriate pediatric ARVs, but what about other disease areas? And what are the obstacles in developing the right neglected disease technologies for children more broadly? After a little digging, a few important issues came forward.

New Technologies. There is undoubtedly a need for new neglected disease technologies for children, especially in diagnostics.

Tuesday morning, the Global Health Council and the American Enterprise Institute hosted a congressional briefing, “Substandard Medicines and the Developing World,” at The Hill to examine the impact of substandard medicines in the global supply chain and the impact of these products on global health. Smita Baruah, CEO of the Global Health Council, moderated the discussion and speakers included Rep. G.K.

Did you enjoy our PDP mini-series from August? This is a guest blog post from the International AIDS Vaccine Initiative (IAVI) that gives a deeper insight on how IAVI handles IP issues.

In The Gridlock Economy, Columbia Law School professor Michael Heller explains how too much ownership wrecks markets, stops innovation, and costs lives. Ownership itself isn’t the problem, he writes; it’s that today’s increasingly complex economies get stuck in yesterday’s property rights management.